

## **CMA Media Release**

**24 April 2018**

### **CMA congratulates Blackmores on investment in Australian manufacturing**

Chief executive officer of Complementary Medicines Australia (CMA), Mr Carl Gibson, today welcomed the news that well-known industry member, Blackmores, has made a strategic investment in Australian manufacturing in a full acquisition of the world-class Catalent Australia tablet and soft-gel capsule manufacturing facility in Braeside, Victoria.

Mr Gibson said: “This acquisition of a quality Australian manufacturing facility by Blackmores is a demonstration of the industry’s strong commitment to the growth of local high-skilled manufacturing and Australian jobs.”

“Leading firms within the Australian complementary medicines industry consistently deliver on their pledge to meet consumer demand for quality natural products, by delivering on research and development, product innovation, sustainability and supply continuity.”

“Australian complementary medicines are valued here in Australia and across Asia. The *2017 CMA Australian Complementary Medicines Industry Audit* found that the high demand for Australian natural health products had doubled the industry export business in just two years, largely due to the growing popularity of Australia’s high quality products in Asia. This has boosted jobs in the sector across a range of areas, and contributed to the development of employment opportunities in product innovation, scientific evaluation, research and high-skilled manufacturing. “

“The Asia-Pacific region is the largest market for complementary medicines products in the world, and the demand for Australian complementary medicines is expected to remain strong. With this high international demand, the sector holds great potential to continue to expand.”

“Australia’s complementary medicines industry is backed by a regulatory regime that is regarded as one of the strongest in the world. Complementary medicines must be manufactured under pharmaceutical standard Good Manufacturing Practice (GMP) in TGA approved and licensed facilities, where strict safety and quality regulations are enforced. This enables us to manufacture products that meet the highest standards of quality and safety.”

“Investment in Australian manufacturing allows our industry to deliver on its potential for growth and build on the strength of our global branding for excellence,” said Mr Gibson.

ENDS

#### **For Media Interviews or Further Information Contact:**

CMA, Chief Executive

Carl Gibson

+61 457 028 974